Drug Trial Radar · NCT05353894
Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GNS561 After One Single Dose (50 and 200mg) in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Apr 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
27
Planned (sponsor's estimate)
Start
May 2, 2022
Primary completion
Nov 30, 2022
Study completion Nov 30, 2022
Sponsor
- Lead sponsor
- Genoscience PharmaIndustry
- Sponsor type
- Industry
- First posted
- Apr 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
GNS561 is a drug used in preliminary phase 1b study for treatment of patients with primary and secondary liver cancer. The formulation used was oral capsule.The objective of this study in healthy volunteers is to compare pharmacokinetics, safety and tolerability of different formulations (tablets and capsules) and dosage (50 and 200mg) of GNS561 after single oral administration in first part and to evaluate the food effect on pharmacokinetics in second part.
Conditions
- Primary Liver Cancer
Interventions
GNS561 oral tablets and capsulesDrug
Two formulations and Two dosage will be compared
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse EventsTime frame: from first administration until 29 days
- Maximum Plasma Concentration (Cmax)Time frame: Day 1, Day 2, Day 3, Day 4 and Day 7
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Genoscience Pharma
Marseille, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.